Simplify Asset Management Inc. Sells 130,948 Shares of Compass Pathways PLC Sponsored ADR $CMPS

Simplify Asset Management Inc. cut its holdings in shares of Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) by 45.2% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 159,052 shares of the company’s stock after selling 130,948 shares during the quarter. Simplify Asset Management Inc. owned about 0.12% of Compass Pathways worth $880,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Hennion & Walsh Asset Management Inc. grew its stake in shares of Compass Pathways by 169.0% in the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 424,800 shares of the company’s stock worth $2,931,000 after acquiring an additional 266,908 shares during the last quarter. Jefferies Financial Group Inc. acquired a new position in Compass Pathways during the 3rd quarter valued at $7,890,000. Blue Owl Capital Holdings LP raised its stake in Compass Pathways by 163.1% during the 3rd quarter. Blue Owl Capital Holdings LP now owns 604,914 shares of the company’s stock valued at $3,466,000 after purchasing an additional 375,000 shares during the last quarter. BIT Capital GmbH boosted its holdings in Compass Pathways by 2,963.4% in the 4th quarter. BIT Capital GmbH now owns 288,814 shares of the company’s stock valued at $1,993,000 after purchasing an additional 279,386 shares during the period. Finally, Eagle Health Investments LP boosted its holdings in Compass Pathways by 62.4% in the 4th quarter. Eagle Health Investments LP now owns 1,519,388 shares of the company’s stock valued at $10,484,000 after purchasing an additional 583,938 shares during the period. 46.19% of the stock is currently owned by institutional investors and hedge funds.

Compass Pathways Stock Performance

Shares of CMPS stock opened at $13.62 on Friday. Compass Pathways PLC Sponsored ADR has a 52-week low of $3.24 and a 52-week high of $15.40. The stock has a market cap of $1.84 billion, a price-to-earnings ratio of -4.32 and a beta of 2.47. The company has a debt-to-equity ratio of 0.15, a quick ratio of 3.32 and a current ratio of 3.32. The firm has a fifty day moving average of $11.56 and a 200-day moving average of $8.37.

Compass Pathways (NASDAQ:CMPS) last issued its earnings results on Wednesday, May 13th. The company reported ($0.30) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.15. On average, equities research analysts forecast that Compass Pathways PLC Sponsored ADR will post -1.24 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on CMPS. Royal Bank Of Canada raised their price target on shares of Compass Pathways from $21.00 to $22.00 and gave the stock an “outperform” rating in a research report on Thursday, May 14th. HC Wainwright reaffirmed a “buy” rating on shares of Compass Pathways in a research report on Friday, May 22nd. UBS Group set a $18.00 target price on shares of Compass Pathways in a research note on Thursday, May 7th. Morgan Stanley lifted their target price on Compass Pathways from $16.00 to $17.00 and gave the stock an “overweight” rating in a research report on Thursday, May 14th. Finally, BTIG Research restated a “buy” rating and set a $14.00 price target on shares of Compass Pathways in a research note on Wednesday, May 13th. Two research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $23.10.

Compass Pathways Company Profile

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.